DiaMedica Appoints Dr. Todd Verdoorn as Vice President of Neuroscience
Minneapolis, Minnesota – (Marketwire – Janaury 20, 2016) – DiaMedica Inc. (TSX-V:DMA) (OTCQB: DMCAF) (“DiaMedica”), today announced the appointment of Dr. Todd Verdoorn as DiaMedica’s Vice President of Neuroscience. Dr. Verdoorn has more than 26 years of experience working with both public and private companies to develop new treatments for neurological diseases, including five years working wth Bristol-Myers Squibb’s stroke group.
Dr. Verdoorn earned his PhD in Neurobiology from the University of North Carolina, conducting his post-doctoral research at the Max Planck Institute with Nobel Laureate Dr. Bert Sakmann and served as Associate Professor of Pharmacology at Vanderbilt University School of Medicine.
“We are pleased to welcome Dr. Verdoorn to our team,” said Rick Pauls, President & Chief Executive Officer of DiaMedica. “His knowledge and experience in stroke will help DiaMedica as we focus our efforts on acute ischemic stroke.”
“I am very happy to be joining the DiaMedica team and am very excited about the prospects for its lead compound, DM199, in neurological indications, particularly ischemic stroke,” said Dr. Todd Verdoorn.
DiaMedica is a publicly traded clinical stage biopharmaceutical company focused on developing novel treatments for stroke and other vascular diseases. DiaMedica's common shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”.
For further information please contact:
President & CEO
Two Carlson Parkway, Suite 165
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica’s expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. Forward looking statements in this news release include, but are not limited to, the Company’s objectives, goals, future plans and statements regarding the use of proceeds from the private placement. Factors that could cause actual results to differ materially from such forward-looking information described in detail in the DiaMedica’s filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.